AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

TKNO · NASDAQ · Drug Manufacturers - Specialty & Generic

Alpha Teknova

Makes catalog and custom reagents for therapy, vaccine, diagnostic, and research workflows.

$7.12

After-hours close+0.01 (+0.14%)

At close$7.11(−2.74%)

Something off on this page? Send us feedback.

Profile

Alpha Teknova, Inc.TKNOHealth Care

Sells lab-essential and clinical-solution reagents, including media plates, culture media, supplements, and molecular biology products. Revenue is mostly U.S.-based, and execution depends on fast-turnaround formulation, quality systems, and manufacturing capacity at its Hollister campus.

Supplies catalog and custom reagents for life-science workflows, with Lab Essentials covering routine and customer-specified formulations and Clinical Solutions covering custom GMP-grade products. Product types include pre-poured media plates, liquid microbial culture media and supplements, and molecular biology reagents.

Serves pharmaceutical and biotechnology companies, CDMOs, diagnostic franchises, academic institutions, and government research institutions. Customer revenue is concentrated in the United States, while the business operates from a Hollister manufacturing campus with formulation, dispensing, packaging, quality-control, inventory, warehouse, and clean-room capacity.

Competes on turnaround time, product performance, and quality against large life-science suppliers, niche reagent makers, and customers that can produce similar inputs in-house. Clinical work depends on quality-system capabilities for components used in diagnostic and therapeutic products.

Company facts

CEOStephen Gunstream

ListedJun 25, 2021

ExchangeNASDAQ

HeadquartersHollister, CA

CountryUnited States

Employees158

CIK0001850902

ISINUS02080L1026

Key statistics

Market cap$381.7M

EPS (ttm)−$0.3150

P/E (ttm)−22.60

ROE-24.9%

P/B6.10

P/S8.74

Dividend yield—

Beta1.41vs XLV 0.74

Year to date +82.3% · Average volume (30d) 224.2K

Analysts

Price target, next 12 months$7.50+5.3%Median of 3 analysts · vs the Aug 28 close

ConsensusBuy3 of 3 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $7.12

High$8.00+12.4%

Median$7.50+5.3%

Low$7.00−1.7%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Target
Aug 11, 2026	BTIG	Upgrade	Neutral	Buy	$8
Aug 5, 2026	Roth Capital	Initiate		Buy	$7

Earnings

EPS

Estimate−$0.06

ReportedDue Nov 5, 2026

Revenue

Estimate$11.7M

ReportedDue Nov 5, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 5, 2026Q2 FY26	−$0.08	−$0.06	+28.8%	$11.0M	$12.2M	+11.3%	+16.40%
May 6, 2026Q1 FY26	−$0.09	−$0.08	+13.6%	$10.2M	$11.1M	+8.3%	+9.89%
Feb 26, 2026Q4 FY25	−$0.09	−$0.09	0.0%	$9.7M	$10.0M	+3.0%	+13.16%
Nov 6, 2025Q3 FY25	−$0.09	−$0.08	+14.7%	$9.6M	$10.5M	+8.7%	−2.08%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$9.8M	$10.3M	$10.5M	$10.0M	$11.1M	$12.2M
Gross profit	$3.0M	$4.0M	$3.2M	$3.2M	$3.5M	$4.9M
Operating income	−$5.0M	−$3.4M	−$4.0M	−$4.6M	−$4.3M	−$2.9M
Net income	−$4.6M	−$3.6M	−$4.3M	−$4.8M	−$4.6M	−$3.2M
Diluted EPS	−$0.09	−$0.07	−$0.08	−$0.09	−$0.09	−$0.06
Gross margin	30.7%	38.7%	30.7%	32.5%	31.6%	40.1%
Operating margin	-50.7%	-32.9%	-38.4%	-46.2%	-38.8%	-23.7%

Fiscal years (4-quarter sums)FY21 $36.9M · FY22 $41.4M · FY23 $36.7M · FY24 $37.7M · FY25 $40.5M

Revenue by product · Q2 FY26

Lab Essentials$9.2M · 75%

Clinical Solutions$2.4M · 20%

Other Product$573.0K · 5%

Revenue by geography · Q2 FY26

United States$11.7M · 96%

Non-US$526.0K · 4%

Balance sheet, Jun 30, 2026Cash & short-term investments $17.4M · Total debt $27.4M · Total assets $95.9M · Shareholders' equity $62.6M

Dividends

No dividends on record.

Ownership

Institutions 14.24%7.63M sharesInsiders 1.23%659.8K sharesOther 84.53%45.32M shares

Shares outstanding 53.61M · Float 10.85M · 20.2% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Roubaix Capital, LLC	1.88M	3.51%	13F	May 6, 2026
Royce & Associates LP	1.07M	1.99%	13F	May 12, 2026
BlackRock, Inc.	716.8K	1.34%	13F	May 13, 2026
Millennium Management LLC	447.1K	0.83%	13F	May 15, 2026
Vanguard Capital Management LLC	441.9K	0.82%	13F	May 15, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Mar 6, 2026	Stephen Gunstream	director, officer: President and CEO	+26,000	$2.15
Mar 6, 2026	Matthew Lowell	officer: Chief Financial Officer	+40,000	$2.19